Minigastrin I (human)

CAS No. 60748-07-4

Minigastrin I (human)( ——— )

Catalog No. M40217 CAS No. 60748-07-4

Minigastrin is an acidic peptide. Minigastrin can be used to study peptidepeptide interaction.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote Get Quote
50MG Get Quote Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Minigastrin I (human)
  • Note
    Research use only, not for human use.
  • Brief Description
    Minigastrin is an acidic peptide. Minigastrin can be used to study peptidepeptide interaction.
  • Description
    Minigastrin is an acidic peptide. Minigastrin can be used to study peptidepeptide interaction.
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    60748-07-4
  • Formula Weight
    1645.66
  • Molecular Formula
    C74H99N15O26S
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Woods AS,et al. A study of peptide--peptide interaction by matrix-assisted laser desorption/ionization. J Am Soc Mass Spectrom. 2001;12(1):88-96. ?
molnova catalog
related products
  • AS 602801

    AS 602801(Bentamapimod) is a novel, orally active inhibitor of JNK.

  • Carbazochrome

    Carbazochrome?is an antihemorrhagic, or hemostatic, agent that will cease blood flow by causing the aggregation and adhesion of platelets in the blood to form a platelet plug, ceasing blood flow from an open wound.

  • SM-102

    SM-102 is an ionizable amino lipid that can be used for the formation of lipid nanoparticles (LNPs). SM-102 has the potential for development of lipid nanoparticles for delivery of mRNA-based vaccines.